Back
HuagongsheHuagongshe Chemistry Print Report · For research reference only
HCID 65327Generated: October 26, 2026

Desipramine Hydrochloride

https://huagongshe.com/en/chemical/65327

Desipramine Hydrochloride molecular structure

Identifiers & Physical Properties

CAS No.58-28-6
Molecular formulaC18H23ClN2
Average molar mass302.8 g/mol
Monoisotopic mass302.15497642 g/mol
SMILESCNCCCN1c2ccccc2CCc2ccccc21.Cl
InChIKeyXAEWZDYWZHIUCT-UHFFFAOYSA-N
PubChem CID65327
ChEMBLCHEMBL1696
EC No.200-373-1
DTXSIDDTXSID9046942

Chemical & Physical Properties

Topological polar surface area15.3
Hydrogen bond donors2
Hydrogen bond acceptors2
Rotatable bonds4
Heavy atoms21
Formal charge0
Complexity267
Solubility>45.4 [ug/mL] (The mean of the results at pH 7.4)
Human DrugsFDA approved drugs -> Active ingredient
Collision Cross Section162.1 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]

Safety & Regulations

GHS classificationDangerH302 (97.9%): Harmful if swallowed [Warning Acute toxicity, oral]P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, P403+P233, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 47 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Regulatory informationStatus: Active Update: 07-12-2017 https://echa.europa.eu/registration-dossier/-/registered-dossier/213405H-Dibenzb,fazepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Other safety informationIMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N-methyl-, monohydrochloride: Human health tier I assessment
Hazard Classes and CategoriesAcute Tox. 4 (97.9%)
Drug Induced Liver InjuryDrug Induced Liver Injury Rank (DILIrank 2.0)Desipramine hydrochlorideAmbiguous-DILI-concern3Adverse reactionsDOI:10.1016/j.drudis.2016.02.015